P=N/A, N=60, Completed, Affiliated Hospital of Jining Medical University; Affiliated Hospital of Jining Medical University

P2, N=66, Recruiting, OHSU Knight Cancer Institute | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026

OLN significantly improves memory and antioxidant levels while reducing cytokine levels, although its effects on kidney function are limited. These results underscore the intricate relationship between OLN, cognitive function, and renal health.

Post-treatment, the treatment group's SDS scores decreased from 42.64 ± 6.32 to 37.06 ± 8.34 (P<0.001), and SAS scores dropped from 50.48 ± 12.94 to 43.61 ± 13.47 (P<0.001). Anxiety and depression impair immune function in lung cancer patients, while olanzapine enhances CD3, CD4, and NK cell activity and reduces psychological distress, suggesting its potential as an adjunct in cancer immunotherapy.

P2, N=384, Completed, Yale University | Recruiting --> Completed

P=N/A, N=3000, Recruiting, Boryung Pharmaceutical Co., Ltd

P1, N=20, Completed, University Hospital, Basel, Switzerland | Recruiting --> Completed

Molecular docking demonstrated strong binding affinities between olanzapine and these targets, with docking scores ranging from - 5.3 to - 8.8 kilocalories per mole (kcal/mol). These findings suggest that olanzapine, as an antipsychotic, may alleviate acute agitation symptoms by modulating signaling pathways associated with neuroinflammation and neuroplasticity, providing a basis for further research into its mechanism of action in neuropsychiatric disorders.

Preclinical studies highlight the promise of small-molecule inhibitors, repurposed agents (e.g., sorafenib, artesunate, trifluoperazine), natural compounds (e.g., piperlongumine, Evodia lepta, quercetin), and nanomedicine platforms for targeted ferroptosis induction. Future research should focus on developing pharmacologically viable GPX4 inhibitors, refining biomarker-driven patient stratification, and designing multimodal regimens that combine ferroptosis induction with standard therapies while preserving immune and tissue integrity. Ferroptosis therefore represents both a mechanistic framework and a translational opportunity to reshape oral oncology and broader oral disease management.

P4, N=24, Terminated, The Guthrie Clinic | N=104 --> 24 | Trial completion date: Nov 2029 --> Jul 2025 | Recruiting --> Terminated | Trial primary completion date: Nov 2028 --> Jul 2025; Study stopped due to lower than expected accrual.

The CFRGs risk prognosis model can effectively predict patients' immune infiltration and immunotherapy response, providing a new reference basis for individualized treatment plans for COAD patients.

P=N/A, N=5000, Recruiting, Massachusetts General Hospital